Article Information
- Received July 4, 2022
- Revision received November 30, 2022
- Accepted December 18, 2022
- First published January 3, 2023.
- Version of record published February 8, 2023.
Author Information
- Panos Zanos1,2,5,
- Kyle A. Brown1,
- Polymnia Georgiou1,3,
- Peixiong Yuan4,
- Carlos A. Zarate Jr4,
- Scott M. Thompson1,5, and
- Todd D. Gould1,6,7,8
- 1Department of Psychiatry, School of Medicine, University of Maryland, Baltimore, Maryland 21201
- 2Department of Psychology, University of Cyprus, Nicosia 2109, Cyprus
- 3Department of Biology, University of Cyprus, Nicosia 2109, Cyprus
- 4Experimental Therapeutics and Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland 20892
- 5Department of Physiology, School of Medicine, University of Maryland, Baltimore, Maryland 21201
- 6Department of Pharmacology, School of Medicine, University of Maryland, Baltimore, Maryland 21201
- 7Department of Anatomy & Neurobiology, School of Medicine, University of Maryland, Baltimore, Maryland 21201
- 8Veterans Affairs Maryland Health Care System, Baltimore, Maryland 21201
Author contributions
Author contributions: P.Z., K.A.B., C.A.Z., S.M.T., and T.D.G. designed research; P.Z., K.A.B., P.G., and P.Y. performed research; P.Z. analyzed data; P.Z. and T.D.G. wrote the first draft of the paper; K.A.B., P.G., P.Y., C.A.Z., and S.M.T. edited the paper.
Disclosures
- Received July 4, 2022.
- Revision received November 30, 2022.
- Accepted December 18, 2022.
This research was supported by the National Institutes of Health Grant MH107615, United States Department of Veterans Affairs Merit Awards 1I01BX004062 and 101BX003631, an Allergan Pharmaceuticals Investigator-Initiated Research Grant (T.D.G.), the National Institutes of Health Grant MH086828 (to S.M.T.), and the Brain and Research Foundation Young Investigator Grant National Alliance for Research on Schizophrenia and Depression Grant 26826 (to P.Z.). We thank Ms. Thatchana Rajasekar for her technical assistance in analyzing the novel object recognition experiments. We also thank Dr. Patrick Morris who characterized the GluN2A PAM, GNE-5729.
T.D.G. has received research funding from Roche Pharmaceuticals and served as a consultant for FSV7 LLC, during the preceding three years. C.A.Z. is listed as a co-inventor on a patent for the use of ketamine in major depression and suicidal ideation. P.Z., C.A.Z., and T.D.G. are listed as co-authors in patents and patent applications related to the pharmacology and use of (2R,6R)-HNK in the treatment of depression, anxiety, anhedonia, suicidal ideation, and posttraumatic stress disorders. S.M.T. is listed as an inventor on a patent for the use of GABA-NAMs for treatment of depression. All other authors declare no competing financial interests. C.A.Z. has assigned his patent rights to the Unites States Government but will share a percentage of any royalties that may be received. P.Z., S.M.T., and T.D.G. have assigned patent rights to the University of Maryland, Baltimore, MD, but will share a percentage of any royalties that may be received by the University of Maryland.
- Correspondence should be addressed to Todd D. Gould at gouldlab{at}me.com or Panos Zanos at zanos.panos{at}ucy.ac.cy
Funding
HHS | NIH | National Institute of Mental Health (NIMH)
MH107615; MH086828; MH086828veterans administration
1I01BX004062; 101BX003631Brain and Research Foundation
26826
Other Version
- previous version (January 03, 2023).
- You are viewing the most recent version of this article.
